NS-2359

NS-2359
NS-2359
Systematic (IUPAC) name
(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(methoxymethyl)-8-azabicyclo[3.2.1]octane
Clinical data
Pregnancy cat.  ?
Legal status  ?
Identifiers
ATC code None
PubChem CID 11408320
Chemical data
Formula C15H19Cl2NO 
Mol. mass 300.223 g/mol
SMILES eMolecules & PubChem
 YesY(what is this?)  (verify)

NS-2359 (GSK-372,475) is a serotonin-norepinephrine-dopamine reuptake inhibitor. It was under development by GlaxoSmithKline (GSK) as an antidepressant,[1] but was discontinued in 2009 when phase II clinical trials turned up disappointing results and did not support further effort by the company.[1] NS-2359 was also in clinical trials for the treatment of ADHD,[2] phase II having been completed in 2007.[3] A trial exploring the effect of NS-2359 on cocaine-experienced individuals is currently ongoing.[4]

See also

References